These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 26433449)

  • 21. Discovery of a novel series of indolinylpyrimidine-based GPR119 agonists: Elimination of ether-a-go-go-related gene liability using a hydrogen bond acceptor-focused approach.
    Kamaura M; Kubo O; Sugimoto H; Noguchi N; Miyashita H; Abe S; Matsuda K; Tsujihata Y; Odani T; Iwasaki S; Murata T; Sato K
    Bioorg Med Chem; 2021 Mar; 34():116034. PubMed ID: 33548803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-throughput screening for GPR119 modulators identifies a novel compound with anti-diabetic efficacy in db/db mice.
    Zhang M; Feng Y; Wang J; Zhao J; Li T; He M; Yang D; Nosjean O; Boutin J; Renard P; Wang MW
    PLoS One; 2013; 8(5):e63861. PubMed ID: 23704946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists.
    Zuo Z; Chen M; Shao X; Qian X; Liu X; Zhou X; Xiang J; Deng P; Li Y; Jie H; Liu C; Cen X; Xie Y; Zhao Y
    Bioorg Med Chem Lett; 2020 Feb; 30(4):126855. PubMed ID: 31898998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of a novel series of GPR119 agonists: Design, synthesis, and biological evaluation of N-(Piperidin-4-yl)-N-(trifluoromethyl)pyrimidin-4-amine derivatives.
    Kubo O; Takami K; Kamaura M; Watanabe K; Miyashita H; Abe S; Matsuda K; Tsujihata Y; Odani T; Iwasaki S; Kitazaki T; Murata T; Sato K
    Bioorg Med Chem; 2021 Jul; 41():116208. PubMed ID: 34010766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of a novel series of indoline carbamate and indolinylpyrimidine derivatives as potent GPR119 agonists.
    Sato K; Sugimoto H; Rikimaru K; Imoto H; Kamaura M; Negoro N; Tsujihata Y; Miyashita H; Odani T; Murata T
    Bioorg Med Chem; 2014 Mar; 22(5):1649-66. PubMed ID: 24508142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis, and biological evaluation of aryl N-methoxyamide derivatives as GPR119 agonists.
    Jang YK; Lee KM; Jung KY; Kang SK; Pagire SH; Lee JM; Pagire HS; Kim KR; Bae MA; Lee H; Rhee SD; Ahn JH
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3909-3914. PubMed ID: 28666737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
    Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
    J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of a potent G-protein-coupled receptor 119 agonist for the treatment of type 2 diabetes.
    Pola S; Shah SR; Pingali H; Zaware P; Thube B; Makadia P; Patel H; Bandyopadhyay D; Rath A; Giri S; Patel JH; Ranvir RK; Sundar SR; Patel H; Kumar J; Jain MR
    Bioorg Med Chem; 2021 Apr; 35():116071. PubMed ID: 33611013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenylalanine derivatives as GPR142 agonists for the treatment of type II diabetes.
    Du X; Kim YJ; Lai S; Chen X; Lizarzaburu M; Turcotte S; Fu Z; Liu Q; Zhang Y; Motani A; Oda K; Okuyama R; Nara F; Murakoshi M; Fu A; Reagan JD; Fan P; Xiong Y; Shen W; Li L; Houze J; Medina JC
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6218-23. PubMed ID: 22926069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine.
    Kong D; Guo S; Yang Y; Guo B; Xie X; Hu W
    Bioorg Med Chem Lett; 2019 Mar; 29(6):848-852. PubMed ID: 30685095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery, optimisation and in vivo evaluation of novel GPR119 agonists.
    Brocklehurst KJ; Broo A; Butlin RJ; Brown HS; Clarke DS; Davidsson Ö; Goldberg K; Groombridge SD; Kelly EE; Leach A; McKerrecher D; O'Donnell C; Poucher S; Schofield P; Scott JS; Teague J; Westgate L; Wood MJ
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7310-6. PubMed ID: 22061639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conformational restriction in a series of GPR119 agonists: differences in pharmacology between mouse and human.
    Scott JS; Brocklehurst KJ; Brown HS; Clarke DS; Coe H; Groombridge SD; Laber D; MacFaul PA; McKerrecher D; Schofield P
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3175-9. PubMed ID: 23628336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis and biological activity of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists.
    Li Z; Wang X; Xu X; Yang J; Xia W; Zhou X; Huang W; Qian H
    Bioorg Med Chem; 2015 Nov; 23(22):7158-64. PubMed ID: 26482570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization of oxadiazole derivatives with a spirocyclic cyclohexane structure as novel GPR119 agonists.
    Harada K; Mizukami J; Watanabe T; Mori G; Ubukata M; Suwa K; Fukuda S; Negoro T; Sato M; Inaba T
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2100-2106. PubMed ID: 31288965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-Hydroxy-eicosapentaenoic acid is an endogenous GPR119 agonist and enhances glucose-dependent insulin secretion.
    Kogure R; Toyama K; Hiyamuta S; Kojima I; Takeda S
    Biochem Biophys Res Commun; 2011 Dec; 416(1-2):58-63. PubMed ID: 22079287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry.
    Li Z; Yang J; Wang X; Li H; Liu C; Wang N; Huang W; Qian H
    Bioorg Med Chem; 2016 Nov; 24(21):5449-5454. PubMed ID: 27624524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of a novel potent GPR40 full agonist.
    Meegalla SK; Huang H; Martin T; Xu J; Zhao S; Liu J; Hall M; Gunnet J; Wang Y; Rady B; Silva J; Otieno M; Arnoult E; Paul Lee S; Pocai A; Player MR
    Bioorg Med Chem Lett; 2018 Feb; 28(4):720-726. PubMed ID: 29366647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design.
    Sheng R; Yang L; Zhang Y; Xing E; Shi R; Wen X; Wang H; Sun H
    Bioorg Med Chem Lett; 2018 Aug; 28(15):2599-2604. PubMed ID: 29980358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.
    Hamdouchi C; Maiti P; Warshawsky AM; DeBaillie AC; Otto KA; Wilbur KL; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Cr S; Lineswala JP; Neathery GL; Bouaichi C; Diseroad BA; Campbell AN; Sweetana SA; Adams LA; Cabrera O; Ma X; Yumibe NP; Montrose-Rafizadeh C; Chen Y; Miller AR
    J Med Chem; 2018 Feb; 61(3):934-945. PubMed ID: 29236497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.